Department of Cardiovascular Diseases, Mayo Clinic, Jacksonville, Florida, USA.
Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Catheter Cardiovasc Interv. 2021 Mar;97(4):736-742. doi: 10.1002/ccd.29459. Epub 2021 Jan 11.
Transcatheter aortic valve-in-valve replacement (ViV) has been widely accepted as a less invasive alternative to treat failed aortic surgical or transcatheter bioprosthetic valves. Angulated aortas present an additional challenge, particularly when using self-expanding transcatheter heart valves (SE-THV).
Two patients with failed surgical bioprosthetic aortic valves and one patient with a failed transcatheter bioprosthetic aortic valve underwent transcatheter aortic ViV using SE-THV. All were deemed high-risk for surgical aortic valve replacement by a heart team. All three patients had initial failed SE-THV delivery using a conventional approach with subsequent successful delivery using the endovascular snare technique.
In Cases 1 and 2, the SE-THV was biased towards the greater curve of the angulated aorta and behind the outer frame of the bioprosthetic valve frame. An endovascular snare was deployed through a secondary left femoral artery access, and the valve delivery system was advanced through the snare in the ascending aorta. The snare was tightened around the SE-THV capsule proximal to the hat-marker, allowing deflection of the SE-THV and successful delivery. In Case 3, the SE-THV interacted with the tall frame of a failed SE-THV. A snare via the left femoral artery was deployed in the descending artery. The SE-THV was advanced through the snare, and both the snare and SE-THV were advanced together to the ascending aorta where the SE-THV was deflected and successfully delivered.
The endovascular snare technique is a feasible option for successful delivery of SE-THV during transcatheter aortic ViV in failed transcatheter or surgical bioprosthetic valves in angulated aortas.
经导管主动脉瓣中瓣置换术(ViV)已被广泛接受,成为治疗失败的主动脉外科或经导管生物瓣的一种微创替代方法。主动脉弯曲增加了额外的挑战,特别是在使用自膨式经导管心脏瓣膜(SE-THV)时。
两名失败的外科生物瓣主动脉瓣患者和一名失败的经导管生物瓣主动脉瓣患者接受了 SE-THV 的经导管主动脉 ViV。所有患者均由心脏团队评估为外科主动脉瓣置换的高危患者。所有三名患者最初均采用常规方法进行 SE-THV 输送,但随后均采用血管内圈套技术成功输送。
在病例 1 和 2 中,SE-THV 偏向于弯曲主动脉的较大曲线,并位于生物瓣框架的外框架后面。通过第二根股动脉的辅助通道部署血管内圈套,然后通过圈套将瓣膜输送系统推进升主动脉。圈套收紧在 SE-THV 胶囊靠近帽标记器的近端,允许 SE-THV 偏转而成功输送。在病例 3 中,SE-THV 与失败的 SE-THV 的高框架相互作用。通过股动脉部署左股动脉的圈套。将 SE-THV 穿过圈套推进,然后将圈套和 SE-THV 一起推进至升主动脉,在此处 SE-THV 被偏转而成功输送。
在经导管主动脉 ViV 中,对于失败的经导管或外科生物瓣的弯曲主动脉,血管内圈套技术是成功输送 SE-THV 的可行选择。